Doshi Dipal, CEO, reported a transaction classified as withholding at Entrada Therapeutics, Inc. involving 17566.000000 shares for an estimated $205146.29. Reported holdings after the transaction were 424387.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
Form 4 relationship flags and nearby filing context
CEO
Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stoc…
This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.30 to $11.95, inclusive. The reporting person undertakes to provi…
25% of the option shares shall vest and become exercisable on March 1, 2026, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will b…
0 other filings
0 recent txs